Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination ...

Cutting-edge clinical research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is being shared this ...